Brexpiprazole (formerly OPC-34712; OPC34712; Rexulti) is a novel D2 dopamine partial agonist [also called serotonin-dopamine activity modulator (SDAM)] approved as an atypical antipsychotic drug. IT inhibits 5-HT2A receptor with a Ki value of 0.47 nMr. Although it failed Phase II clinical trials for ADHD, it has been designed to provide improved efficacy and tolerability (e.g., less akathisia, restlessness and/or insomnia) over established adjunctive treatments for major depressive disorder (MDD). Brexpiprazole was approved on 7/10/2015 for the treatment of schizophrenia, and as an adjunctive treatment for depression.

纯度：≥98%

CAS：913611-97-9